CytRx (CYTR) Sees Unusually-High Trading Volume

CytRx Co. (NASDAQ:CYTR) saw unusually-high trading volume on Tuesday . Approximately 2,931,699 shares changed hands during mid-day trading, an increase of 644% from the previous session’s volume of 393,833 shares.The stock last traded at $2.27 and had previously closed at $1.83.

Separately, ValuEngine cut shares of CytRx from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st.

The company has a market cap of $62.74, a P/E ratio of -0.80 and a beta of 2.26.

CytRx (NASDAQ:CYTR) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter.

A hedge fund recently raised its stake in CytRx stock. Goldman Sachs Group Inc. boosted its position in CytRx Co. (NASDAQ:CYTR) by 795.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 703,465 shares of the biotechnology company’s stock after acquiring an additional 624,863 shares during the period. Goldman Sachs Group Inc. owned about 0.42% of CytRx worth $441,000 at the end of the most recent reporting period. 44.82% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “CytRx (CYTR) Sees Unusually-High Trading Volume” was originally published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/cytrx-cytr-sees-unusually-high-trading-volume/1861000.html.

About CytRx

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.